Markets:

Overview

News

Currencies

International

Treasuries

uniQure N.V. - Ordinary Shares (NQ:QURE)

46.00 +0.32 (+0.70%)

Streaming Delayed Price Updated: 4:00 PM EDT, Sep 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about uniQure N.V. - Ordinary Shares

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

17 18 Next >

Alibaba, Intel, Uniqure, Tesla And Opendoor: Why These 5 Stocks Are On Investors' Radars Today ↗

September 24, 2025

U.S. stocks slipped on Wednesday, with the Nasdaq losing more than 75 points, or 0.3%, to close at 22,497.85.

Via Benzinga

UniQure Stock Hits 5-Year High As Analysts Hail Huntington’s Therapy Data — Retail Spots ‘Diamond In Rough Of Biotech’ ↗

September 24, 2025

UniQure said the high-dose of its AMT-130 therapy slowed Huntington’s disease progression by up to 75% over three years and plans to seek FDA approval in early 2026.

Via Stocktwits

uniQure Announces $200 Million Proposed Public Offering

September 24, 2025

From uniQure Inc.

Via GlobeNewswire

Earnings Scheduled For July 29, 2025 ↗

July 29, 2025

Via Benzinga

uniQure Earnings Preview ↗

July 28, 2025

Via Benzinga

Earnings Outlook For uniQure ↗

May 08, 2025

Via Benzinga

Nasdaq Down Over 100 Points; US Crude Oil Stocks Fall ↗

September 24, 2025

Via Benzinga

What's Going On With UniQure Stock Wednesday? ↗

September 24, 2025

UniQure N.V. (NASDAQ:QURE) shares are trading higher Wednesday after the company announced positive topline results from Phase I/II study of AMT-130 in patients with Huntington's Disease.

Via Benzinga

Lithium Americas, Alibaba, uniQure, IREN, Cidara: Stocks Making The Biggest Moves Today ↗

September 24, 2025

Via Stocktwits

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

September 24, 2025

Via Benzinga

A Cure For Huntington's Disease? UniQure Launches More Than 240%. ↗

September 24, 2025

The company's gene therapy slowed disease progression by 75% over three years.

Via Investor's Business Daily

uniQure Stock Doubles On Promising Data From Huntington's Disease Trial ↗

September 24, 2025

UniQure's AMT-130 gene therapy slowed Huntington's disease progression in a Phase 1/2 trial, supported by new $175 million financing for launch readiness.

Via Benzinga

uniQure Stock Rises Pre-Market After Investigational Huntington’s Disease Drug Slows Disease In Trial ↗

September 24, 2025

The company stated that high-dose AMT-130 demonstrated 75% disease slowing at 36 months, as measured by the composite Unified Huntington's Disease Rating Scale.

Via Stocktwits

uniQure Announces Refinancing of Existing $50 Million Debt and Securing Up to an Additional $125 Million in Non-Dilutive Funding

September 24, 2025

From uniQure Inc.

Via GlobeNewswire

uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington’s Disease

September 24, 2025

From uniQure Inc.

Via GlobeNewswire

uniQure's Investigational Gene Therapy Shows Promising Efficacy With Manageable Safety Risks For Fabry Disease ↗

September 05, 2025

uniQure's early AMT-191 trial data in Fabry disease showed strong enzyme activity, manageable safety, and patient independence from enzyme replacement therapy.

Via Benzinga

uniQure Announces Initial AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease

September 05, 2025

From uniQure Inc.

Via GlobeNewswire

FDA Outlines Process To Speed Up Rare Disease Therapy Approvals ↗

September 04, 2025

FDA launches Rare Disease Evidence Principles to guide therapy reviews, offering new pathways for approval while raising questions on development impact.

Via Benzinga

Vinay Prasad's Comeback To FDA Sparks Debate Over Regulatory Direction ↗

August 11, 2025

Vinay Prasad returns as FDA's CBER director after brief exit, raising questions on rare disease drug approvals and mRNA vaccine oversight.

Via Benzinga

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday? ↗

July 30, 2025

Vinay Prasad exits FDA's biologics division following pressure over Sarepta's Elevidys approval and regulatory controversies.

Via Benzinga

uniQure Narrows Loss in Fiscal Q2 ↗

July 29, 2025

Via The Motley Fool

uniQure NV (NASDAQ:QURE) Posts Q2 2025 Earnings: EPS Beat Offsets Revenue Miss as Regulatory Progress Boosts Shares ↗

July 29, 2025

uniQure NV reports mixed Q2 2025 results with revenue missing estimates but EPS beating forecasts. Shares rise on regulatory progress for Huntington's gene therapy AMT-130.

Via Chartmill

uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress

July 29, 2025

From uniQure Inc.

Via GlobeNewswire

uniQure to Announce Second Quarter 2025 Financial Results

July 22, 2025

uniQure to host earnings call on Tuesday, July 29, 2025 at 8:30 a.m. ET

From uniQure Inc.

Via GlobeNewswire

uniQure Announces Appointment of Kylie O’Keefe as Chief Customer and Strategy Officer

June 11, 2025

From uniQure Inc.

Via GlobeNewswire

uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease

June 02, 2025

From uniQure Inc.

Via GlobeNewswire

uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE)

May 29, 2025

From uniQure Inc.

Via GlobeNewswire

UniQure Narrows Q1 Loss But Revenue Plummets: Retail’s In Wait-And-Watch Mode ↗

May 09, 2025

The company narrowed its first-quarter loss to $0.82 per share, down from $1.36 per share in 2024.

Via Stocktwits

uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress

May 09, 2025

From uniQure Inc.

Via GlobeNewswire

Earnings Scheduled For May 9, 2025 ↗

May 09, 2025

Via Benzinga

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.